Shares of WuXi AppTec Co., Ltd. (OTCMKTS:WUXAY – Get Free Report) saw an uptick in trading volume on Friday. 54,913 shares changed hands during trading, an increase of 1,091% from the previous session’s volume of 4,612 shares. The stock last traded at $25.00 and had previously closed at $25.80.
Analysts Set New Price Targets
Separately, Zacks Research cut shares of WuXi AppTec from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 5th. One research analyst has rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy”.
View Our Latest Stock Report on WUXAY
WuXi AppTec Price Performance
The firm has a 50 day moving average of $25.82 and a 200-day moving average of $20.48.
About WuXi AppTec
WuXi AppTec is a contract research, development and manufacturing organization (CRDMO) that provides services to pharmaceutical, biotechnology and medical-device companies. Its offerings span the drug-development process, including early-stage discovery, medicinal and synthetic chemistry, biology research, analytical testing, preclinical studies, clinical research support, process development and commercial manufacturing.
The company supports a broad range of therapeutic programs, with capabilities covering small-molecule drugs, biologics, chemical and pharmaceutical products, and cell and gene therapies.
Featured Articles
- Five stocks we like better than WuXi AppTec
- Bank of America Stock Sell-Off Looks Like a Buying Opportunity
- AST SpaceMobile Is Down 67%—Could SpaceX’s Mobile Push Deepen the Selloff?
- GlobalFoundries’ $21 Billion Deal Could Change the Economics of Chipmaking
- Fundamental and Technicals Signals Align for Costco: Is the Stock Finally Breaking Out?
Receive News & Ratings for WuXi AppTec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for WuXi AppTec and related companies with MarketBeat.com's FREE daily email newsletter.
